Adaptimmune Therapeutics PLC (NASDAQ:ADAP) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Thursday.

Other analysts also recently issued research reports about the stock. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research report on Sunday. Cowen and Company reissued a “buy” rating on shares of Adaptimmune Therapeutics PLC in a research report on Tuesday, June 6th. Finally, Zacks Investment Research downgraded shares of Adaptimmune Therapeutics PLC from a “buy” rating to a “hold” rating in a research report on Monday. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $12.08.

Shares of Adaptimmune Therapeutics PLC (ADAP) traded up 1.02% on Thursday, reaching $5.94. 113,358 shares of the company were exchanged. The company has a 50-day moving average price of $4.97 and a 200 day moving average price of $4.84. Adaptimmune Therapeutics PLC has a 1-year low of $3.76 and a 1-year high of $8.89.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last posted its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.06. The business had revenue of $2.86 million for the quarter, compared to analyst estimates of $5.07 million. Adaptimmune Therapeutics PLC had a negative return on equity of 41.40% and a negative net margin of 550.22%. Equities analysts predict that Adaptimmune Therapeutics PLC will post ($1.04) EPS for the current fiscal year.

WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/07/20/adaptimmune-therapeutics-plc-nasdaqadap-lifted-to-sell-at-valuengine.html.

Hedge funds have recently modified their holdings of the stock. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter valued at about $120,000. KCG Holdings Inc. purchased a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter valued at about $133,000. Monashee Investment Management LLC purchased a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter valued at about $138,000. Paloma Partners Management Co purchased a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter valued at about $165,000. Finally, Creative Planning increased its stake in shares of Adaptimmune Therapeutics PLC by 32.8% in the first quarter. Creative Planning now owns 40,500 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 10,000 shares during the period. 56.15% of the stock is owned by institutional investors.

Adaptimmune Therapeutics PLC Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.